Company news
Shandong Boan Biotechnology Company., Limited news
Latest news releases, newest first.
Voluntary announcement the company enters into licensing agreement for denosumab injection 60 mg in Japan
October 30, 2026
Voluntary announcement first subject enrolled in phase i clinical trial of BA1203 (a masked anti-PD-1/IL-2 fusion protein) in China
October 22, 2026
Continuing connected transactions promotion cooperation agreement
October 9, 2026
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 7, 2026
Interim report 2026
September 29, 2026
Next Day Disclosure Return
September 17, 2026
Voluntary announcement cde approval of IND application for BA1203 (a masked anti-PD-1/IL-2 fusion protein)
September 14, 2026
Poll results of the annual general meeting held on 22 June 2026
June 22, 2026
Voluntary announcement licensing of dulaglutide injection in the U.S.
June 11, 2026